Literature DB >> 2432130

The glycine-alanine repeating region is the major epitope of the Epstein-Barr nuclear antigen-1 (EBNA-1).

H Rumpold, G H Rhodes, P L Bloch, D A Carson, J H Vaughan.   

Abstract

The Epstein-Barr nuclear antigen-1 (EBNA-1) is a protein containing a large glycine-alanine repeat that has been shown to be antigenic. Antibodies to EBNA-1 can be detected by means of immunoblotting. Preincubation of antisera with purified EBNA-1 protein inhibits the binding of IgG antibodies in this system, indicating that those epitopes detected by immunoblots are also accessible on the native molecule. A number of synthetic peptides the sequences of which were derived from the glycine-alanine repeating region of EBNA-1 and from regions adjacent to it also inhibited antibody binding to EBNA-1. These showed, however, a 1000-fold variation in their inhibitory activities. Peptides containing only glycine and alanine were the most effective inhibitors. The anti-EBNA-1 antibodies did not react with several other peptides representing sequences from unrelated proteins. At saturating concentrations of peptide 85 to 100% of anti-EBNA-1, antibody binding was inhibited in all sera tested with one exception. Similar results are obtained when antibody binding is assayed by an enzyme immunosorbent assay by using partially purified EBNA-1 to coat the plates. Thus the glycine-alanine region, either through its primary structure or through conformations assumed by this region, forms the major epitope(s) of the EBNA-1 molecule.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2432130

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  Elevated immunoglobulin G antibodies to the proline-rich amino-terminal region of Epstein-Barr virus nuclear antigen-2 in sera from patients with systemic connective tissue diseases and from a subgroup of Sjögren's syndrome patients with pulmonary involvements.

Authors:  M Yamazaki; R Kitamura; S Kusano; H Eda; S Sato; M Okawa-Takatsuji; S Aotsuka; K Yanagi
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

2.  An immunodominant site of gamma-zein1 is in the region of tandem hexapeptide repeats.

Authors:  A Esen
Journal:  J Protein Chem       Date:  1990-08

3.  Epstein-Barr virus nuclear antigen 1 linear epitopes that are reactive with immunoglobulin A (IgA) or IgG in sera from nasopharyngeal carcinoma patients or from healthy donors.

Authors:  H M Cheng; Y T Foong; C K Sam; U Prasad; J Dillner
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

4.  Evaluation of antibodies against different Epstein-Barr virus nuclear antigen 1 peptides in diagnosis of nasopharyngeal carcinoma.

Authors:  Ai-Di Gu; Hao-Yuan Mo; Jin-Xin Bei; Yan-Bo Xie; Li-Zhen Chen; Qi-Sheng Feng; Tiebang Kang; Yi-Xin Zeng
Journal:  Clin Vaccine Immunol       Date:  2009-03-11

5.  Epstein-Barr virus serologic abnormalities and risk of rheumatoid arthritis among women.

Authors:  Barbara L Goldstein; Lori B Chibnik; Elizabeth W Karlson; Karen H Costenbader
Journal:  Autoimmunity       Date:  2011-10-20       Impact factor: 2.815

6.  EBNA-1: a virally induced nuclear antigen of primate lymphocytes and its expression in Drosophila cells.

Authors:  A J MacGillivray; M J Allday; S E Saunders; J H Sinclair
Journal:  Br J Cancer Suppl       Date:  1988-12

7.  Molecular cloning of a cDNA encoding the human Sm-D autoantigen.

Authors:  L A Rokeach; J A Haselby; S O Hoch
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

8.  Mutational analysis of Epstein-Barr virus nuclear antigen 1 (EBNA 1).

Authors:  M Polvino-Bodnar; J Kiso; P A Schaffer
Journal:  Nucleic Acids Res       Date:  1988-04-25       Impact factor: 16.971

Review 9.  The Epstein-Barr virus in autoimmunity.

Authors:  J H Vaughan
Journal:  Springer Semin Immunopathol       Date:  1995

10.  Use of enzyme-linked immunosorbent assays with chimeric fusion proteins to titrate antibodies against Epstein-Barr virus nuclear antigen 1.

Authors:  N Inoue; J Kuranari; S Harada; H Nakajima; M Ohbayashi; Y Nakamura; N Miyasaka; K Ezawa; F Ban; K Yanagi
Journal:  J Clin Microbiol       Date:  1992-06       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.